Skip to main content
OpenTrials
Completed

NCT Number: NCT05374564

Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy

18F-Flutemetamol (Vizamyl) is a radioactive diagnostic agent indicated and FDA-approved for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline. This study is designed to evaluate a novel use for 18F-Flutemetamol in cardiac amyloidosis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cardiomyopathies, Primary Amyloidosis, Hereditary, Transthyretin-Related Cardiomyopathies Cardiovascular Diseases Heart Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Yale University

New Haven, Connecticut, 06520, United States

About this study

The goal of this project is to perform a proof-of-concept study to compare the ability of quantitative parametric cardiac 18F-flutemetamol positron emission tomography (PET) to assess baseline and change in disease burden after six months of therapy with tafamidis treatment in 12 patients diagnosed with transthyretin cardiac amyloidosis (ATTR-CA) at Yale-New Haven Hospital. The primary outcome of the study will be comparisons in the magnitude of change in regional and global 18F-flutemetamol cardiac PET metrics between the baseline and six-month 18F-flutemetamol PET scans versus clinical stage and echocardiographic features (wall thickness, strain, LVEF).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1. Age > 18 years
  • 2. Diagnosis of ATTR cardiac amyloidosis (wild-type or V142I ATTR mutation)

a. Diagnosis of ATTR cardiac amyloidosis by established consensus diagnostic criteria of Gillmore et al. (either invasive or non-invasive diagnostic pathways)

  • 3. Plan for initiation of tafamidis therapy for clinical indications and agree to continue tafamidis during the duration of the study.
  • 4. Stated willingness to comply with all study procedures and availability for the duration of the study
  • 5. Able to understand and sign the informed consent document after the nature of the study has been fully explained.
  • 6. Women of childbearing potential who are sexually active with a non-sterilized male partner and males who are sexually active with a partner of childbearing potential must agree to use adequate contraception from screening until 30 days after the Flutemetamol.

Exclusion criteria

  • 1. Primary amyloidosis (AL) or secondary amyloidosis (AA).
  • 2. Prior liver or heart transplantation.
  • 3. Active malignancy or non-amyloid disease with an expected survival of less than 1 year
  • 4. Inability to lie flat for 60 minutes in the PET scanner
  • 5. History of prior treatment for ATTR cardiomyopathy and/or amyloid neuropathy, or decline clinical tafamidis treatment.
  • 6. Pregnancy or lactation
  • 7. Known allergic reactions to components of the 18F-flutemetamol and/or polysorbate 80
  • 8. High risk for non-adherence as determined by screening evaluation.

Treatment and study plan

(18F)Flutemetamol

Drug

18F-Flutemetamol binds to β-amyloid plaques and the F-18 isotope produces a positron signal that is detected by a PET scanner. Multiple recent studies have shown that thioflavin-analogue tracers such as 18F-flutemetamol may be able to fulfill the unmet need of elucidating the presence of amyloid deposition in the heart. Because it binds to the beta-pleated motif of the amyloid fibril due to their similarity to the thioflavin structure, 18F-Flutemetamol could potentially be used to image cardiac amyloidosis (CA)

Other names: Vizamyl

Primary outcomes

  1. Determine if ATTR cardiomyopathy disease severity is associated with increased 18F-flutemetamol

    Time frame: 6 months

    As determined by comparisons in the magnitude of change in regional and global 18F-flutemetamol cardiac PET visual uptake scores between the baseline and six-month PET scans

  2. Determine if ATTR cardiomyopathy disease severity is associated with increased 18F-flutemetamol

    Time frame: 6 months

    As determined by comparisons in the magnitude of change in regional and global 18F-flutemetamol cardiac PET percent maximal counts between the baseline and six-month PET scans

  3. Determine if ATTR cardiomyopathy disease severity is associated with increased 18F-flutemetamol

    Time frame: 6 months

    As determined by comparisons in the magnitude of change in regional and global 18F-flutemetamol cardiac PET Standardized Uptake Values (SUVs) between the baseline and six-month PET scans

  4. Determine if ATTR cardiomyopathy disease severity is associated with increased 18F-flutemetamol

    Time frame: 6 months

    As determined by comparisons in the magnitude of change in regional and global 18F-flutemetamol cardiac PET retention index between the baseline and six-month PET scans

  5. Determine if ATTR cardiomyopathy disease severity is associated with increased 18F-flutemetamol

    Time frame: 6 months

    As determined by comparisons in the magnitude of change in regional and global 18F-flutemetamol cardiac PET Vt between the baseline and six-month PET scans

  6. Determine if treatment with tafamidis reduces 18F-flutemetamol cardiac PET imaging markers

    Time frame: 6 months

    As assessed by dynamic cardiac PET between baseline and 6 months

Secondary outcomes

  1. Compare changes in 18F-flutemetamol PET variables and measures of ATTR clinical response

    Time frame: 6 months

    As determined by ATTR clinical stage baseline and following 6 months of treatment with tafamidis.

  2. Compare changes in 18F-flutemetamol PET variables and measures of ATTR clinical response

    Time frame: 6 months

    As determined by NT-proBNP between baseline and following 6 months of treatment with tafamidis.

  3. Compare changes in 18F-flutemetamol PET variables and measures of ATTR clinical response

    Time frame: 6 months

    As determined by TnT between baseline and following 6 months of treatment with tafamidis.

  4. Compare changes in 18F-flutemetamol PET variables and measures of ATTR clinical response

    Time frame: 6 months

    As determined by echocardiographic wall thickness between baseline and following 6 months of treatment with tafamidis.

  5. Compare changes in 18F-flutemetamol PET variables and measures of ATTR clinical response

    Time frame: 6 months

    As determined by global longitudinal strain between baseline and following 6 months of treatment with tafamidis.

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

  • Pfizer

Registry information

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
May 16, 2022
Registry last updated
Aug 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.